Special Issue

Osteosarcomas: Treatment Strategies

Message from the Guest Editor

Osteosarcoma, also known as bone tumor, generally affects children and adolescents. According to the latest cancer statistics, osteosarcoma was ranked as having the lowest five-year relative survival rate among the most common childhood and adolescent cancers in the United Sates. Since modern therapeutic methods have developed rapidly, the outcome for patients with osteosarcoma has improved. Typical treatments for osteosarcoma include surgery and intensive chemotherapy. However, with respect to recurrent and metastatic osteosarcoma, existing treatments, including surgery and chemotherapy, exhibit a limited therapeutic effect. Therefore, it is necessary to develop new therapeutic strategies to treat osteosarcoma. Pharmaceuticals invites both original research articles and reviews shedding light on recent challenges in developing therapeutic strategies for the treatment of osteosarcoma. Topics of interest include drug development, drug repositioning, selective optimization of the lead compound, and drug combinations. The collection of manuscripts will be published as a Special Issue of the journal.

Guest Editor

Dr. See-Hyoung Park

Department of Biological and Chemical, Hongik University, Sejong, Republic of Korea

Deadline for manuscript submissions

closed (31 January 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/58272

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

